David H. Jones

For Corporates
Analyzing Healthcare M&A Trends: Q1 2024 Insights
Healthcare M&A activity remained robust in the first quarter of 2024, with 29 transactions vs. 28 in 2023. Biopharma was the most active healthcare subsector, representing 45% of deal volume, while Services activity remained dampened despite notable transactions such as Novo Holdings’ acquisition of Catalent. We expect Biopharma M&A activity to remain robust as large pharmaceutical companies attempt to fill revenue and pipeline gaps via acquisitions of late- or commercial-stage companies. We expect pre-commercial biopharma companies to continue pursue strategic alternatives, including mergers, private company mergers and cash-out transactions as a result of the dynamic capital markets environment.
LEARN MORE
For Investors
Sectors
Insights
About
- Firm
- Careers
- News
- Contact
- Transactions

Team
Related Team
David H. Jones

David Jones is a Senior Managing Director of Institutional Equities at Leerink Partners.

David brings over 20 years of experience and expertise in Sales & Trading to Leerink Partners. He joined the Firm in 2015 as a Director of Institutional Sales Trading providing coverage to predominantly Boston and West Coast based institutional clients. Prior to Leerink Partners, David held similar positions at FBR Capital Markets, Lazard Capital Markets, KeyBanc Capital Markets, and Salomon Smith Barney. He started his career in the MBA Training Program at Salomon Brothers.

He graduated Cum Laude from Harvard University.

Partner With Us

Contact Us